Vericel Corp(VCEL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 92.84 | EPS (ttm) | 0.46 | Insider Own | 1.19% | Shs Outstand | 51.2M | Perf Week | -0.14% |
| Market Cap | 2.20B | Forward P/E | 49.54 | EPS next Y | 61.92% | Insider Trans | -15.35% | Shs Float | 50.6M | Perf Month | 6.9% |
| Enterprise Value | 2.13B | PEG | 0.81 | EPS next Q | 0.06 | Inst Own | 108.15% | Short Float | 10.35% | Perf Quarter | -6.64% |
| Income | 0.02B | P/S | 7.17 | EPS this Y | 67.19% | Inst Trans | -2.29% | Short Ratio | 10.1 | Perf Half Y | 23.55% |
| Sales | 0.31B | P/B | 5.93 | EPS next 5Y | 61.01% | ROA | 5.16% | Short Interest | 5.24M | Perf YTD | 19.16% |
| Book/sh | 7.23 | P/C | 13.53 | EPS past 3/5Y | - 39.2% | ROE | 7.16% | 52W High | -13% ($49.32) | Perf Year | 23.02% |
| Cash/sh | 3.17 | P/FCF | 35.64 | Sales past 3/5Y | 18.9% 17.34% | ROIC | 5.38% | 52W Low | 48.22% ($28.95) | Perf 3Y | 30.74% |
| Dividend Est. | - | EV/EBITDA | 68.36 | EPS Y/Y TTM | 228.76% | Gross Margin | 74.56% | Volatility(W/M) | 4.02% 3.64% | Perf 5Y | -6.76% |
| Dividend TTM | - | EV/Sales | 6.95 | Sales Y/Y TTM | 22.95% | Oper. Margin | 5.95% | ATR (14) | 1.51 | Perf 10Y | 1725.96% |
| Dividend Ex-Date | - | Quick Ratio | 4.69 | EPS Q/Q | 483.64% | Profit Margin | 7.91% | RSI (14) | 58.28 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.04 | Sales Q/Q | 22.48% | SMA20 | 4.38% ($41.11) | Beta | 1.09 | Target Price | $59.71 |
| Payout | - | Debt/Eq | 0.26 | Earnings | 2026/11/5 | SMA50 | 5.64% ($40.62) | Rel Volume | 1.05 | Prev Close | $41.09 |
| Employees | 398 | LT Debt/Eq | 0.22 | EPS/Sales Surpr. | 238.41% 6.54% | SMA200 | 11.06% ($38.64) | Avg Volume(3M) | 0.52M | Price | $42.91 |
| IPO | 1997/2/4 | Option/Short | Yes/Yes | Trades | 6404 | Volume | 544,634 | Change | 4.43% |
A US biotech company that develops and commercializes cell therapy and regenerative medicine products. It markets and supplies cartilage regeneration therapies using patients' own cells, skin cell therapies for severe burns, and burn treatment products, with a focus on sports medicine and burn care. The company has established itself as a biotech player with a commercialized portfolio of cell therapy and regenerative medicine products.
Over the past 1 year, roughly in the middle
13% below its 1-year high.
Traded about as much as usual. That is 105% of its average volume.
Next earnings report: November 5
6 days to go.
VCEL makes money exceptionally well
Of every $100 in sales, $5.95 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +67.2% this year.
Tap to view numbers
However, it looks expensive
For a company expected to earn $100 next year, you would pay $4,954. Peers typically go for $2,616. Compared with its own 3-year average, it is 65% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -6.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 108.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #93 of 594 in the industry
Based on market cap of $2B.
FAQ
What kind of company is VCEL?
VCEL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VCEL?
The market cap of VCEL is approximately $2.2B, ranking 1,988 within its sector.
What is the P/E ratio of VCEL?
VCEL has a P/E ratio of approximately 92.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for VCEL?
VCEL has recorded a 52-week high of $49.32 and a low of $28.95.
